SD BioScience-Novocellbio, Agreement for Joint Entry into the Immune Cell Therapy Market

Photo by SD Bioscience

[Asia Economy Reporter Jang Hyowon] SD Bioscience announced on the 30th that it has signed a memorandum of understanding (MOU) with Novocellbio to jointly enter the immune cell therapy market.

Novocellbio is a company researching and developing NK cell-based immune cell therapies and possesses unique technologies related to large-scale cultivation and activation maximization, which are core competencies in NK cell therapy development. The company is conducting clinical trials domestically and internationally for NK cell-based lymphoma, liver cancer, lung cancer, and COVID-19 treatments, and is actively expanding overseas business based on favorable data.

In February, Novocellbio agreed to continue expanding indications by starting clinical trials for COVID-19 with the Mexican TecSalud General Hospital consortium and adding clinical trials for breast cancer. Among the hospitals in the TecSalud General Hospital consortium, Zambrano Hellion Hospital and San Jose Hospital have maintained the 3rd and 4th highest rankings in Mexico for several years and host clinical centers of multinational pharmaceutical companies within their facilities.

SD Bioscience and Novocellbio plan to operate immune cell therapy centers domestically and internationally based on clinical results, starting by establishing an immune cell therapy center in Japan to preoccupy the NK cell therapy market. Accordingly, on the 12th, both companies will visit candidate sites in Japan to promptly establish the immune cell therapy center. Additionally, both companies agreed to expand the immune cell therapy market by establishing treatment centers in the Middle East to enter the European and Middle Eastern markets.

Novocellbio is exploring global combination clinical trials of anticancer drugs and NK cells with major global pharmaceutical companies and is promoting technology exports to the United States, Europe, and the Middle East. Along with the realization of these achievements, it has agreed with SD Bioscience to proceed with overseas and domestic listings jointly.

Furthermore, based on the research and development achievements made so far, SD Bioscience and Novocellbio agreed to actively promote business from 2023 and enhance corporate value as a leading company in immune cell therapy to maximize shareholder value.